ADImmune Corporation Plans To Sell Its Flu Vaccine In China This Year

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

January 7, 2013 -- Adimmune of Taiwan has completed a China Phase III trial of its trivalent flu vaccine in 1,200 people. It expects CFDA approval in mid-2014, which will allow the company to market the vaccine in mainland China in time for the 2014-2015 flu season, making it the first Taiwanese company to provide a vaccine to China. Adimmune is the only GMP-certified vaccine maker in Taiwan. More details....

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC